Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Ath – page 89

1 642 clinical trials in Ath, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Ath at a glance
1 642
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 642 trials in Ath

Open in trial search

Study of Debio 4228 for Patients with Advanced or Metastatic Prostate Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Degarelix
  • Sponsor:Debiopharm International S.A.

Hepatic cirrhosis

Not recruiting

Study of Resmetirom in Patients with Well-compensated Non-alcoholic Steatohepatitis (NASH) Cirrhosis to Evaluate Effects on Liver Health

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Resmetirom
  • Sponsor:Madrigal Pharmaceuticals Inc.

Study on Tolebrutinib for Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Tolebrutinib
  • Sponsor:Genzyme Corp.

Study on Palbociclib and Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib
  • Sponsor:ABCSG GmbH

Study of Encorafenib, Cetuximab, and Pembrolizumab for Patients with Untreated BRAF V600E-Mutant Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Pfizer Inc.

Breast cancer+1

Not recruiting

Study of Tucatinib and Ado-Trastuzumab Emtansine for Patients with Advanced HER2+ Breast Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tucatinib
  • Sponsor:Seagen Inc.

Study on MaaT013 for Treating Acute Gastrointestinal Graft-Versus-Host Disease in Patients Not Responding to Ruxolitinib

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Faecal Microbiota, Pooled
  • Sponsor:Maat Pharma

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

Study on the Effects of Casimersen and Golodirsen for Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Casimersen
  • Sponsor:Sarepta Therapeutics Inc.

Study on Zolbetuximab and mFOLFOX6 for Patients with Advanced Gastric or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Astellas Pharma Global Development Inc.

Study Comparing Datopotamab Deruxtecan and Docetaxel for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Daiichi Sankyo Inc.

Dermatitis atopic

Not recruiting

Study on the Effectiveness of Ruxolitinib Cream for Adults with Moderate Atopic Dermatitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Ath

What the registry says about research in the country

01 Cardiovascular and Cerebrovascular Research

Clinical research in Ath addresses critical cardiovascular conditions, particularly focusing on cerebrovascular events. Investigations center on acute ischemic stroke and high-risk transient ischemic attack, conditions that represent significant causes of disability and mortality. These studies aim to evaluate novel therapeutic approaches designed to reduce the risk of recurrent ischemic events in patients who have experienced these serious cerebrovascular incidents.

  • Assessment of innovative pharmacological interventions for stroke prevention
  • Evaluation of treatment strategies to minimize recurrent cerebrovascular events
  • Investigation of therapeutic efficacy in acute cerebrovascular conditions
  • Research focused on improving outcomes for patients with transient ischemic attacks

The research underway seeks to establish safer and more effective treatment protocols for individuals at elevated risk of stroke, potentially improving long-term neurological outcomes and quality of life for affected patients.

02 Oncology and Gastrointestinal Cancer Research

Ath hosts clinical investigations in the field of oncology, with particular emphasis on gastrointestinal malignancies. Research efforts concentrate on locally advanced rectal cancer, examining treatment strategies tailored to specific patient populations. These trials explore different approaches to neoadjuvant therapy, which involves treatment administered before surgical intervention, aiming to optimize the balance between treatment effectiveness and patient safety.

  • Comparison of conventional neoadjuvant therapy versus total neoadjuvant therapy approaches
  • Evaluation of treatment efficacy and safety profiles in older cancer populations
  • Investigation of optimal timing and sequencing of chemotherapy and radiation therapy
  • Research on personalized treatment strategies for rectal cancer management

These studies are particularly significant as they address the unique needs of older patients with rectal cancer, seeking to identify treatment regimens that maximize therapeutic benefit while minimizing adverse effects in this vulnerable population.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.